Teplizumab safety tracked for over 3 years in young diabetes patients
Disease control
Ongoing
This study follows 188 children and adolescents who completed the PROTECT study to check the long-term safety of teplizumab, an antibody treatment for recent-onset type 1 diabetes. Researchers will monitor side effects, insulin use, and blood sugar control for an additional 42 mo…
Sponsor: Provention Bio, a Sanofi Company • Aim: Disease control
Last updated Jun 15, 2026 19:07 UTC